BioNTech SE (BNTX) Return on Capital Employed (2019 - 2025)
BioNTech SE (BNTX) reported Return on Capital Employed of 6.85% for Q4 2025, down 28.0% on a YoY basis from 9.51% in Q4 2024, and down 47.77% sequentially from 4.63% in Q3 2025.
BioNTech SE (BNTX) Return on Capital Employed (2019 - 2025) Analysis & Trends
BioNTech SE (BNTX) has 7 years of Return on Capital Employed data on file, last reported at 6.85% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 28.0% year-over-year to 6.85%; the trailing twelve-month figure through Dec 2025 stood at 6.85% (down 28.0% YoY), and the FY2025 full-year result was 7.2%, down 74.0% from the prior year.
- Return on Capital Employed declined to 6.85% in Q4 2025, from 4.63% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 178.73% in Q2 2021 to a low of 6.85% in Q4 2025.
- A 5-year average of 54.91% and a median of 23.11% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 19951 bps in 2021 and sank 8983 bps in 2023, its largest moves.
- Tracing BNTX's Return on Capital Employed over 5 years: stood at 133.74% in 2021, then plunged by 35 bps to 87.6% in 2022, then slumped by 96 bps to 3.3% in 2023, then sank by 299 bps to 6.57% in 2024, then decreased by 4 bps to 6.85% in 2025.
- Business Quant data shows BNTX's Return on Capital Employed at 6.85% in Q4 2025, 4.63% in Q3 2025, and 4.5% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | BioNTech SE | 22.13 Bn | 22.13 Bn | 668.28 Mn | -6.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.85% |
| Sep 30, 2025 | -4.63% |
| Jun 30, 2025 | -4.50% |
| Mar 31, 2025 | -6.64% |
| Dec 31, 2024 | -6.57% |
| Sep 30, 2024 | -4.71% |
| Jun 30, 2024 | -4.41% |
| Mar 31, 2024 | -2.28% |
| Dec 31, 2023 | 3.30% |
| Sep 30, 2023 | 15.88% |
| Jun 30, 2023 | 30.34% |
| Mar 31, 2023 | 55.99% |
| Dec 31, 2022 | 87.60% |
| Sep 30, 2022 | 105.71% |
| Jun 30, 2022 | 119.74% |
| Mar 31, 2022 | 137.26% |
| Dec 31, 2021 | 133.74% |
| Sep 30, 2021 | 159.16% |
| Jun 30, 2021 | 178.73% |
| Mar 31, 2021 | 111.40% |